Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285518 · ClinicalTrials.gov registry record · Phase 1
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01285518 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 84 participants.
The verdict
NCT01285518, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
Interventions
- DRUG PF-05231023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285518
The ClinicalTrials.gov registry entry for NCT01285518 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05231023 is the first listed.
NCT01285518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285518 about?
NCT01285518 is a clinical study titled "Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes". This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
What is the current status of trial NCT01285518?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2011-02. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01285518?
The interventions under investigation include: PF-05231023 (DRUG).
Who is sponsoring clinical trial NCT01285518?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.